NCT04682327Unknown不适用
Observational Study on the Relationship Between Gut Microbiota and Immunotherapy Response of Non-small Cell Lung Cancer
Shanghai Zhongshan Hospital1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2021年8月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Diversity and Composition of gut microbiota
研究概览
简要总结
This study will analyze the composition and diversity of the gut microbiota of patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) through metagenomic high-throughput sequencing methods, and explore the relationship between the gut microbiota and anti-PD-1/PD-L1 treatment response.
This study will further understand the influence and mechanism of the gut microbiota on tumor immunotherapy, and will provide new ideas and theoretical basis for improving the efficacy of tumor immunotherapy by targeting the gut microbiota in the clinic, and benefit more NSCLC patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Volunteer to participate in this trial, fully understand this trial, and sign the Informed Consent Form (ICF).
- •18-75 years old on the day of signing the ICF.
- •Locally advanced/metastatic non-small cell lung cancer diagnosed by histology or cytology. no epidermal growth factor receptor (EGFR) sensitive mutations, anaplastic lymphoma kinase (ALK) gene rearrangement, ROS Proto-oncogene 1 (ROS1) gene fusion.
- •receive anti-PD-1/PD-L1 for first-line treatment.
- •Have not received systemic treatment for locally advanced/metastatic NSCLC.
- •Have measurable target lesions judged by the investigator according to Response Evaluation Criteria In Solid Tumors (RECIST V1.1).
- •0~1 ECOG score.
- •Life expectancy ≥ 12 weeks.
- •Have sufficient organ function, evaluated based on blood routine, renal function, liver function, and coagulation laboratory test results (and have not received blood transfusion or infusion of apheresis components within 14 days before the study drug administration , Erythropoietin, granulocyte colony stimulating factor and other medical support treatments).
- •Women of Childbearing Potential (WOBCP) must undergo a serum pregnancy test within 7 days before the first medication, and the result is negative; WOBCP or men and their WOBCP partners should agree from signing the ICF to the last one. Take effective contraceptive measures within 6 months after taking the study drug.
排除标准
- •Before the first administration of the trial treatment: a) have received previous systemic cytotoxic chemotherapy for metastatic disease; b) have received other targeted or biological anti-tumor therapy for metastatic disease ; c) received major surgery (<3 weeks before the first dose); d) received lung radiotherapy >30 Gy within 6 months before the first dose of the trial treatment; e) the first trial treatment Palliative radiotherapy was completed within 7 days before administration.
- •Any other form of anti-tumor therapy is expected during the study period.
- •Live virus vaccines have been vaccinated within 30 days before the planned treatment. Seasonal influenza vaccine without live virus is allowed.
- •A history of past malignant disease is known, unless the subject receives potentially curative treatment and there is no evidence of disease recurrence within 5 years after starting treatment.
- •Accompanying known active central nervous system (CNS) metastasis and/or cancerous meningitis.
- •According to the standard of Common Adverse Event Terminology (CTCAE) 4th edition, peripheral neuropathy has been ≥2 grade.
- •Severe hypersensitivity reactions to other monoclonal antibody treatments have occurred in the past.
- •Accompanied by active autoimmune diseases, systemic treatment (ie, use of disease modifiers, corticosteroids or immunosuppressive drugs) is required within the past 2 years.
- •Are receiving long-term systemic steroid therapy. Subjects with asthma who require intermittent use of bronchodilators, inhaled steroids, or topical steroid injections are not excluded.
- •Have received any other anti-PD-1 or PD-L1 or PD-L2 drugs or antibodies in the past, or small molecule therapy that targets other immunomodulatory receptors or mechanisms. Participated in any other anti-PD-1/PD-L1 trials and received anti-PD-1/PD-L1 treatment. Such antibodies include (but are not limited to) antibodies against IDO, PD-L1, IL-2R and GITR.
- •Active infections requiring treatment.
- •Known human immunodeficiency virus (HIV) history (known HIV1/2 antibody positive). Accompanied by known active hepatitis B or C.
- •Being pregnant or breastfeeding, or expecting to conceive or conceive during the period of study drug treatment and within the required contraceptive period after the last administration of the study drug.
- •The researcher believes that there are any circumstances that are not suitable for selection.
结局指标
主要结局
Diversity and Composition of gut microbiota
时间窗: At the end of Cycle 4 (each cycle is 21 days)
The difference of gut microbiota diversity and composition between Responder group with Non-Responder group. Microbiota diversity will be quantified by α-diversity ( Faith's Phylogenetic Diversity) based on meta-genomics sequencing. Microbiota composition will be quantified by the operational taxonomic unit (OTU) in the stool.
次要结局
- Concentration of peripheral blood mononuclear cells(At the end of Cycle 4 (each cycle is 21 days))
- Concentration of tumor immune related cytokines(At the end of Cycle 4 (each cycle is 21 days))
- Incidence of anti-PD-1/PD-L1 related adverse events(through study completion, up to 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
The Gut Microbiota and Delirium in the ICUDelirium of Mixed OriginMicrobial ColonizationNCT03328377Herlev Hospital50
Unknown
不适用
A Study of the Relationship of Gut Microbial Composition and Stroke OutcomeIschemic StrokeNCT03470506University of Virginia300
进行中（未招募）
不适用
Gut Microbiota Profile and Its Impact on Immunity Status in COVID-19 Vaccinated CohortsCOVID-19 VaccinationGut MicrobiotaNCT04980560Chinese University of Hong Kong215
已完成
不适用
Investigation of the Gut Microbiota in Patients With Acute Myeloid LeukemiaCachexiaAcute Myeloid LeukemiaNCT03881826Université Catholique de Louvain60
尚未招募
不适用
A Study About Association Between Microbiome, Metabolome and Clinical Characteristics in COPD PatientsChronic Obstructive Pulmonary DiseaseNCT06101459Asan Medical Center300